Tyme Technologies, Inc. (NASDAQ: TYME) Major Shareholder Sells $ 13,274.25 in Stock


Tyme Technologies, Inc. (NASDAQ: TYMEGet Rating) major shareholder Michael Demurjian sold 53,097 shares of the business’s stock in a transaction on Tuesday, May 31st. The shares were sold at an average price of $ 0.25, for a total transaction of $ 13,274.25. Following the transaction, the insider now owns 23,355,749 shares in the company, valued at approximately $ 5,838,937.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Michael Demurjian also recently made the following trade (s):

  • On Monday, May 16th, Michael Demurjian sold 50,000 shares of Tyme Technologies stock. The stock was sold at an average price of $ 0.25, for a total transaction of $ 12,500.00.
  • On Monday, May 2nd, Michael Demurjian sold 50,000 shares of Tyme Technologies stock. The stock was sold at an average price of $ 0.31, for a total transaction of $ 15,500.00.
  • On Tuesday, April 19th, Michael Demurjian sold 40,000 shares of Tyme Technologies stock. The shares were sold at an average price of $ 0.32, for a total value of $ 12,800.00.
  • On Tuesday, April 12th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $ 0.34, for a total value of $ 6,800.00.
  • On Monday, April 4th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $ 0.35, for a total value of $ 7,000.00.
  • On Monday, March 28th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $ 0.34, for a total value of $ 6,800.00.
  • On Monday, March 21st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The stock was sold at an average price of $ 0.33, for a total transaction of $ 6,600.00.

Tyme Technologies stock opened at $ 0.26 on Thursday. The firm has a 50-day moving average of $ 0.31 and a two-hundred day moving average of $ 0.45. Tyme Technologies, Inc. has a 1 year low of $ 0.22 and a 1 year high of $ 2.02.

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. its stake in Tyme Technologies grew by 8.7% in the third quarter. BlackRock Inc. now owns 2,084,696 shares of the company’s stock worth $ 2,147,000 after purchasing an additional 166,889 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Tyme Technologies in the 3rd quarter worth $ 571,000. Healthcare Value Capital LLC increased its stake in shares of Tyme Technologies by 33.3% during the third quarter. Healthcare Value Capital LLC now owns 2,000,000 shares of the company’s stock valued at $ 2,060,000 after buying an additional 500,000 shares during the period. Morgan Stanley increased its stake in shares of Tyme Technologies by 382.3% during the first quarter. Morgan Stanley now owns 276,924 shares of the company’s stock valued at $ 493,000 after buying an additional 219,507 shares during the period. Finally, GSA Capital Partners LLP raised its holdings in shares of Tyme Technologies by 224.1% in the first quarter. GSA Capital Partners LLP now owns 585,966 shares of the company’s stock valued at $ 205,000 after acquiring an additional 405,143 shares in the last quarter. 21.00% of the stock is owned by hedge funds and other institutional investors.

Tyme Technologies Company Profile (Get Rating)

Tyme Technologies, Inc., a biotechnology company, is developing cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II / III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma.

Featured Stories

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ: TYME)



Receive News & Ratings for Tyme Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analyzes’ ratings for Tyme Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment